Source / episode info
- **Episode:**306
- **Title:**Divine Intervention Episode 306 – USMLE Step 2CK Rapid Review Series 54.
- **Published:**2021-04-16
- Source:Episode page
One-liner
This episode provides a high-yield review of hypercalcemia mechanisms in malignancy (SCLC via PTHrP; MM via IL-6/RANKL; Stägehosis via Vitamin D excess), the step-wise management protocol for acute hypercalcemia, and key concepts regarding B-cell immunodeficiency.
High-yield summary
- Acute Hypercalcemia Management: Always start with IV Normal Saline (NS) to correct volume depletion. If refractory, proceed to IV Bisphosphonates (e.g., pamidronate). Third line is Calcitonin.
- SCLC Mechanism: Parathyroid hormone related peptide (PTHrP) acts on the calcium sensing receptor (CaSR), mimicking PTH and causing hypercalcemia. Look for cavitary lung lesions.
- Multiple Myeloma (MM) Mechanism: Hypercalcemia results from increased osteoclast activity, mediated by cytokines like IL-6, which upregulates RANKL binding to the RANK receptor on osteoclasts. This is independent of PTHrP.
- Stägehosis Mechanism: Granulomatous inflammation leads to high local production of 1--hydroxylase, converting inactive Vitamin D (25-OHD) to active Calcitriol (1,25-dihydroxyvitamin D), causing hypercalcemia.
- Immunodeficiency: Pan-hypogammaglobulinemia (low IgG, IgA, IgM, etc.) in a young child with recurrent infections suggests B-cell impairment (e.g., X-linked Agammaglobulinemia).
Learning objectives
- Differentiate the mechanisms causing hypercalcemia associated with SCLC, Multiple Myeloma, and Stägehosis.
- Outline the three sequential steps for managing acute symptomatic hypercalcemia (NS -> Bisphosphonate -> Calcitonin).
- Recognize the clinical signs of B-cell immunodeficiency based on hypogammaglobulinemia.
- Understand that PTHrP is a peptide hormone mimicking PTH, distinct from true parathyroid overproduction.
- Correlate granulomatous inflammation with excessive Vitamin D activation in Stägehosis.
Board exam buzzwords